The Advent of More Potent ALK Inhibitors
Alice T. Shaw, MD, PhD, from Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors such as LDK378 and the treatment of ALK-positive lung cancer patients with crizotinib.
Clinical Pearls
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors and the treatment of ALK-positive lung cancer patients with crizotinib.
- The treatment of these patients is more complicated now, with the advent of more potent ALK inhibitors
- New ALK inhibitors are potent in patients both resistant and naive to crizotinib
- At a large cancer center, the option exists to start crizotinib as standard therapy or consider a clinical trial with a next-generation ALK inhibitor
- In the community setting, standard procedure would be to start a newly-diagnosed ALK-positive patient on crizotinib
Recent Videos
Related Content
Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC
June 19th 2025Article
During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and compared the use of single agent vs doublet immunotherapy in the PD-L1–low setting.
Read More
